Verrica Pharmaceuticals (NASDAQ: VRCA)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-09 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | -0.250 | 0.2200 | ||||
REV | 431.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Verrica Pharmaceuticals (NASDAQ: VRCA) through any online brokerage.
Other companies in Verrica Pharmaceuticals’s space includes: Opiant Pharma (NASDAQ:OPNT), Cocrystal Pharma (NASDAQ:COCP), SCYNEXIS (NASDAQ:SCYX), Terns Pharma (NASDAQ:TERN) and Ocuphire Pharma (NASDAQ:OCUP).
The latest price target for Verrica Pharmaceuticals (NASDAQ: VRCA) was reported by HC Wainwright & Co. on Tuesday, May 31, 2022. The analyst firm set a price target for 12.00 expecting VRCA to rise to within 12 months (a possible 453.00% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Verrica Pharmaceuticals (NASDAQ: VRCA) is $2.17 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Verrica Pharmaceuticals.
Verrica Pharmaceuticals’s Q2 earnings are confirmed for Tuesday, August 9, 2022.
There is no upcoming split for Verrica Pharmaceuticals.
Verrica Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.